These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The influence of house dust mite sublingual immunotherapy on the TSLP-OX40L signaling pathway in patients with allergic rhinitis. Meng Q; Liu X; Li P; He L; Xie J; Gao X; Wu X; Su F; Liang Y Int Forum Allergy Rhinol; 2016 Aug; 6(8):862-70. PubMed ID: 27012942 [TBL] [Abstract][Full Text] [Related]
4. House dust mite sublingual immunotherapy in allergic rhinitis. Cho SW; Han DH; Kim JW; Kim DY; Rhee CS Immunotherapy; 2018 Jun; 10(7):567-578. PubMed ID: 29562802 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis. Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719 [TBL] [Abstract][Full Text] [Related]
7. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial. Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778 [TBL] [Abstract][Full Text] [Related]
8. Decreased level of osteopontin in children with allergic rhinitis during sublingual immunotherapy. Wang C; Wang K; Liu S; Qin X; Chen K; Zhang T Int J Pediatr Otorhinolaryngol; 2016 Feb; 81():15-20. PubMed ID: 26810282 [TBL] [Abstract][Full Text] [Related]
9. New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases. Ferrando M; Bagnasco D; Passa-Lacqua G; Puggioni F; Varricchi G; Canonica GW Curr Pharm Biotechnol; 2017; 18(5):378-383. PubMed ID: 28413977 [TBL] [Abstract][Full Text] [Related]
10. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial. Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432 [TBL] [Abstract][Full Text] [Related]
11. Role of BAFF in pediatric patients with allergic rhinitis during sublingual immunotherapy. Luo R; Liu W; Wang J; Chen Y; Sun C; Zhou L; Li Y; Deng L Eur J Pediatr; 2014 Aug; 173(8):1033-40. PubMed ID: 24585100 [TBL] [Abstract][Full Text] [Related]
12. Clinical and cytokine responses to house dust mite sublingual immunotherapy. Potter PC; Baker S; Fenemore B; Nurse B Ann Allergy Asthma Immunol; 2015 Apr; 114(4):327-34. PubMed ID: 25661658 [TBL] [Abstract][Full Text] [Related]
13. Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis. Demoly P; Kleine-Tebbe J; Rehm D Allergy; 2017 Oct; 72(10):1576-1578. PubMed ID: 28273339 [TBL] [Abstract][Full Text] [Related]
14. Increase in the prevalence of follicular regulatory T cells correlates with clinical efficacy of sublingual immunotherapy with house dust mites. Murao T; Kouzaki H; Arai H; Matsumoto K; Nakamura K; Kawakita K; Tojima I; Shimizu S; Yuta A; Shimizu T Int Forum Allergy Rhinol; 2024 Jan; 14(1):57-67. PubMed ID: 37345377 [TBL] [Abstract][Full Text] [Related]
15. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. Mosbech H; Canonica GW; Backer V; de Blay F; Klimek L; Broge L; Ljørring C Ann Allergy Asthma Immunol; 2015 Feb; 114(2):134-40. PubMed ID: 25624131 [TBL] [Abstract][Full Text] [Related]
16. SQ house dust mite sublingual immunotherapy for the treatment of adults with house dust mite-induced allergic rhinitis. Meteran H; Backer V Expert Rev Clin Immunol; 2019 Nov; 15(11):1127-1133. PubMed ID: 31584839 [No Abstract] [Full Text] [Related]
17. Single-allergen sublingual immunotherapy versus multi-allergen subcutaneous immunotherapy for children with allergic rhinitis. Wang ZX; Shi H J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):407-411. PubMed ID: 28585143 [TBL] [Abstract][Full Text] [Related]
18. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial. Karakoc-Aydiner E; Eifan AO; Baris S; Gunay E; Akturk E; Akkoc T; Bahceciler NN; Barlan IB J Investig Allergol Clin Immunol; 2015; 25(5):334-42. PubMed ID: 26727762 [TBL] [Abstract][Full Text] [Related]
19. Serum Soluble ST2 Correlated with Symptom Severity and Clinical Response of Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis Patients. Zhu K; Xia C; Chen J; Yu C; Gao T; Yan J; Shao N; Zhu P; Sun B; Ren X; Zhang Y Mediators Inflamm; 2021; 2021():5576596. PubMed ID: 34194284 [TBL] [Abstract][Full Text] [Related]
20. Serum Periostin as a Biomarker for Predicting Clinical Response to House Dust Mite Sublingual Immunotherapy in Allergic Rhinitis. Hoshino M; Akitsu K; Kubota K; Ohtawa J J Allergy Clin Immunol Pract; 2021 May; 9(5):1864-1870. PubMed ID: 33290915 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]